Skip to content

CBB Satisfaction Survey

CBB Satisfaction Survey

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06496347
Enrollment
192
Registered
2024-07-11
Start date
2022-05-09
Completion date
2023-05-18
Last updated
2024-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Cognitive Impairment

Brief summary

The Cogstate Brief Battery (CBB) is a computerized measure for cognitive screening that consists of four cognitive tasks to assess psychomotor function, attention, learning, and working memory, and provides an easy-to-interpret report without the need for manual scoring. Clinical trials and research studies have proven the validity of CBB for cognitive assessment and distinguish MCI or dementia from normal aging. Participants express a growing acceptance of the use of computerized tests for detecting cognitive impairment, viewing it as a potential tool to improve quality of patient care and the patient-clinician relationship when used in conjunction with the human touch. The CBB utilizes non-verbal playing-card stimuli in order to minimize language, educational and cultural biases affecting performance. It has the advantages of being portable (adaptable to notebooks, tablets, and even smart phones), short (20-30 min), game-like in presentation and thus motivating, and cross-culturally adaptable. The CBB is well liked in waiting rooms of primary care settings. It is assumed that the CBB will also be highly accepted by Taiwanese.

Interventions

None listed

Sponsors

Cheng Sheng Chen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

For MCI/dementia groups: Inclusion criteria: 1. Patient diagnosed with MCI, AD dementia, VaD or DLB 2. Participant who is 50-85 years of age 3. Taiwanese who had finished primary education 4. Participant (or legally acceptable representative) who signed the written ICF

Exclusion criteria

1. Participant with GDS score ≥ 10 2. Participant with CDR score \> 1 (Assessment result within 6 months can be used conditionally.) 3. Participant with MMSE score ≤ 17 (MMSE score will be converted from CASI score. Assessment result within 6 months can be used conditionally.) 4. Participant diagnosed with Schizophrenia 5. Participant diagnosed with Parkinson's disease 6. Participant diagnosed with cancer (except basal cell skin carcinoma) in the past two years 7. Participant diagnosed with uncontrolled diabetes 8. Participant with regular alcohol use exceeding two standard drinks per day for women or four per day for men (one standard drink corresponds to 350 cc of beer) 9. Participant unable to take CBB test according to the investigator's discretion, such as blindness 10. Participant who, in the opinion of the investigator or medical monitor, should not participate in the study For HC group: Inclusion criteria: 1. Healthy volunteers without objective cognitive impairment 2. Participant who is 50-85 years of age 3. Taiwanese who had finished primary education 4. Participant who signed the written ICF

Design outcomes

Primary

MeasureTime frameDescription
CBB Testing Score and Brain Age ScoreData analysis and study report: 3 monthsParticipant satisfaction with using CBB will be measured by the paper-and-pencil satisfaction survey including 15 questions. See Appendix 1: Satisfaction Survey for Participant. Score of Question 2 will be ranged from Strongly agree (1) to Strongly disagree (5). Scores of Question 3\ 13 will be ranged from Strongly disagree (1) to Strongly agree (5). The participant satisfaction rates will be estimated from Question 2, 3, 5, 6, 8, 9, 11, 12 and 13, and calculated in accordance with the following formula: Satisfaction rate = (number of score 5 and 4 / number of answers) x 100% The satisfaction rate of each question mentioned above and the frequency of each score of each question will be evaluated and presented by groups of HC and MCI.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026